Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-07934040 + cetuximab
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
PF-07934040 + cetuximab is a combination therapy being studied for advanced solid tumors harboring mutations in the KRAS gene, specifically metastatic colorectal cancer (mCRC)[3]. PF-07934040 is an oral small molecule inhibitor targeting KRAS, a GTPase protein frequently mutated in cancer and responsible for abnormal cellular growth signaling[5]. Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR). This combination is under evaluation to assess safety, tolerability, and preliminary anti-tumor activity in patients with KRAS-mutant mCRC[3]. The developer is Pfizer, and the therapy is currently in Phase 1 clinical trials as a combination[3].
- Other names
- PF-4040PF4040PF 4040
02
Targets
Beyond the preview
Go deeper on PF-07934040 + cetuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-07934040 + cetuximab.